|
|
 |
|
Viewing report
|
|
|
|
China Pharmaceuticals and Healthcare Report Q1 2009
Business Monitor International, March 2009, Pages: 109
BMI's China Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on China's pharmaceuticals and healthcare industry.
Business Monitor International (BMI) expects China’s US$37.0bn pharmaceutical market to post a compound annual growth rate (CAGR) of 13.16% through to 2013, when combined sales of prescription drugs and over-the-counter (OTC) medicines will have reached US$68.0bn. The key drivers are robust economic growth, a growing communicable disease burden, and increased access to healthcare.
China's emerging, but improving, regulatory environment was reinforced by two developments in January 2009. The State Food and Drug Administration (SFDA) has finally banned a dangerous weight loss drug (fenfluramine), and a delegation of regulators took the proactive step and started investigating the distribution of Chinese-made counterfeit medicines in the UK.
Multi-drug resistant tuberculosis (MDR-TB) is a big problem in China. As of December 2008, prevalence is the second highest in the world and distribution varies across the vast country. BMI believes that expenditure on tuberculosis control will increase significantly over the medium term, resulting in a sharp decline in the disease burden. Stakeholders that will see upside are manufacturers of certain antiinfectives, diagnostic companies and testing laboratories.
As of December 2008, the Chinese authorities were considering punishing German firm Siemens for giving kickbacks to state officials. Legal documents obtained by the local media show that they paid US$14.4mn to five public hospitals to secure medical equipment contracts with a value of US$295mn.
A survey jointly conducted by AC Nielsen and the Association of the European Self-Medication Industry (AESGP), released in December 2008, revealed that more than 30% of Chinese respondents preferred self-medication when they suffer from minor health problems such as headache, the common cold and indigestion.
The Ministry of Health, the China Licensed Pharmacists' Association and Pfizer jointly started a two-year training programme for 45,000 doctors on January 9 2009 across China in a bid to control the abuse of antibiotics at public hospitals. The programme aims at ensuring effective and economical use of antibiotics.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
China Pharmaceuticals and Healthcare Report Q3 2009
China Pharmaceuticals and Healthcare Report Q1 2010
China Pharmaceuticals and Healthcare Report Q3 2008
China Pharmaceuticals and Healthcare Report Q4 2009
China Pharmaceuticals and Healthcare Report Q2 2010
Pharmaceutical Industry in China
China Pharmaceuticals and Healthcare Report Q1 2008
Singapore Pharmaceuticals and Healthcare Report Q4 2011
Antibiotics - Global Strategic Business Report
Pain Management - Global Strategic Business Report
|
|
|
|
